Natera (NASDAQ:NTRA) CFO Sells $101,456.18 in Stock

Key Points

• Natera CFO Michael Burkes Brophy sold 482 shares on May 4 at $210.49 for $101,456.18 under a pre-arranged Rule 10b5‑1 plan to cover tax withholding from vested equity, leaving him with 57,496 shares (a 0.83% ownership decrease).
• That May 4 sale is part of a recent selling pattern — Brophy sold multiple blocks this year totaling about $1.33 million, including a $594,782 sale on April 29 — signaling sustained insider liquidity activity.
• NTRA trades near $206.77 with a $29.4B market cap; the company beat quarterly EPS and revenue estimates recently, and Wall Street holds a consensus "Moderate Buy" rating with an average price target of $253.47.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 482 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $210.49, for a total transaction of $101,456.18. Following the sale, the chief financial officer directly owned 57,496 shares in the company, valued at $12,102,333.04. This trade represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, May 1st, Michael Burkes Brophy sold 313 shares of Natera stock. The shares were sold at an average price of $206.16, for a total transaction of $64,528.08.
• On Wednesday, April 29th, Michael Burkes Brophy sold 3,070 shares of Natera stock. The shares were sold at an average price of $193.74, for a total transaction of $594,781.80.
• On Monday, April 27th, Michael Burkes Brophy sold 1,993 shares of Natera stock. The shares were sold at an average price of $204.14, for a total transaction of $406,851.02.
• On Tuesday, March 10th, Michael Burkes Brophy sold 785 shares of Natera stock. The shares were sold at an average price of $204.13, for a total transaction of $160,242.05.

Natera Price Performance

NTRA stock traded down $4.79 during trading on Tuesday, hitting $206.77. 1,065,445 shares of the stock traded hands, compared to its average volume of 1,321,366. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The firm's 50 day moving average is $201.91 and its two-hundred day moving average is $214.51. The stock has a market cap of $29.42 billion, a price-to-earnings ratio of -135.14 and a beta of 1.57.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The company had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. During the same period in the prior year, the firm posted ($0.41) EPS. As a group, analysts anticipate that Natera, Inc. will post -1.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on NTRA shares. Citigroup started coverage on shares of Natera in a report on Wednesday, January 7th. They set a "buy" rating and a $300.00 price target on the stock. Guggenheim raised their price target on shares of Natera from $230.00 to $270.00 and gave the company a "buy" rating in a report on Monday, January 5th. Wall Street Zen raised shares of Natera from a "hold" rating to a "buy" rating in a report on Saturday, April 18th. Robert W. Baird raised their price target on shares of Natera from $239.00 to $257.00 and gave the company an "outperform" rating in a report on Friday, February 27th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Natera in a report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $253.47.

Institutional Trading of Natera

A number of institutional investors have recently made changes to their positions in NTRA. Reflection Asset Management purchased a new position in shares of Natera in the fourth quarter worth approximately $29,000. Palladiem LLC purchased a new position in shares of Natera in the fourth quarter worth approximately $31,000. Horizon Investments LLC purchased a new position in shares of Natera in the third quarter worth approximately $32,000. International Assets Investment Management LLC boosted its holdings in shares of Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company's stock worth $35,000 after buying an additional 97 shares during the last quarter. Finally, Bank of Jackson Hole Trust boosted its holdings in shares of Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company's stock worth $37,000 after buying an additional 83 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.